SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market volatility is rising as investors weigh cooling wholesale inflation against ongoing geopolitical tensions and the impact of climbing bond yields on tech valuations. Community discourse is heavily focused on the sustainability of current market levels, with traders debating whether to buy the dip or prepare for a deeper correction amid a backdrop of high energy costs and potential economic policy shifts.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing significant volatility as investors weigh persistent geopolitical tensions in the Middle East against concerns over surging global bond yields and the heavy debt loads required for AI infrastructure spending. The community is actively debating whether current pullbacks represent a genuine trend reversal or a buying opportunity, with many focusing on the impact of potential trade tariffs and shifting semiconductor sector sentiment.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors react to a rare and significant open-market purchase of company shares by two directors, totaling $2 million in insider buying. The community is actively debating the significance of this move, with some hopeful it signals a bottom and a turnaround for the stock, while others remain skeptical due to ongoing frustration with stagnant price action and the company's long-term patent cliff.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is trending as the stock hits a new 52-week low following a global recall of nearly one million vehicles due to a software defect in rearview cameras. Investors are actively debating the company's valuation, questioning whether the stock is a deep-value opportunity given its significant cash reserves or if persistent operational struggles and inventory issues indicate further downside.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is experiencing significant market interest driven by a strategic global licensing and supply agreement with Samsung, which has heightened expectations that major competitors like Micron will follow with settlements to avoid further litigation. The community is actively debating the company's valuation upside and monitoring upcoming legal milestones, with many long-term holders resisting volatility and short-selling pressure in anticipation of further catalysts.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems shares are experiencing significant volatility following a mixed earnings report where revenue fell short of consensus expectations despite raised full-year guidance. Investors are actively debating the company's valuation, the impact of upcoming share lock-up expirations, and the sustainability of its growth trajectory in the competitive AI hardware landscape.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending as investors reassess broad-market exposure amid ongoing debates over U.S. economic stability, shifting interest rate expectations, and the sustainability of high-valuation tech-driven growth. Community discourse remains centered on whether broad index funds provide a necessary buffer against sector-specific volatility or if targeted growth strategies offer better protection in the current macroeconomic environment.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending as investors react to a rival $37.50 per share buyout bid from an Israeli firm, which surpasses the existing $35 offer from Hapag-Lloyd and potentially bypasses national security concerns regarding the state's 'golden share.' Community discussion is buzzing over the possibility of a bidding war, the potential for continued dividend distributions during the buyout period, and strong underlying shipping fundamentals.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is trending as the sector experiences significant volatility and active institutional rotation, driven by heightened geopolitical tensions in the Middle East that have impacted shipping and crude supply stability. Market participants are intensely debating the durability of recent supply chain disruptions, with community members heavily focused on divergence between paper market pricing and physical inventory shortages.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is facing heightened scrutiny as community discussions weigh strong revenue growth and expanded institutional backing against ongoing concerns regarding high cash burn and potential further dilution. Investors are actively debating the company's long-term commercial potential and management execution while monitoring the stock's recent volatility following a capital raise.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.88% and +9.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug

BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.

FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo

BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.

How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High

BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.

BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?

BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’

Equity

AstraZeneca and Ionis announced on Thursday  that their late-stage CARDIO-TTRansform trial for eplontersen (Wainua) failed to meet its main goal.


BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBIOBridgeBio Pharma Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest BBIO News